GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (MEX:AGIO) » Definitions » Sale Of Property, Plant, Equipment

Agios Pharmaceuticals (MEX:AGIO) Sale Of Property, Plant, Equipment : MXN0.7 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Agios Pharmaceuticals Sale Of Property, Plant, Equipment?

Agios Pharmaceuticals's sale of property, plant, equipment for the three months ended in Sep. 2024 was MXN0.0 Mil. It means Agios Pharmaceuticals gained MXN0.0 Mil from selling property, plant, and equipment. Agios Pharmaceuticals's sale of property, plant, equipment for the trailing twelve months (TTM) ended in Sep. 2024 was MXN0.7 Mil.

Compared with last quarter (MXN0.0 Mil in Jun. 2024 ), Agios Pharmaceuticals gained the same money from selling property, plant, and equipment in Sep. 2024 (MXN0.0 Mil).

Agios Pharmaceuticals Sale Of Property, Plant, Equipment Historical Data

The historical data trend for Agios Pharmaceuticals's Sale Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Sale Of Property, Plant, Equipment Chart

Agios Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sale Of Property, Plant, Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 18.79 22.49

Agios Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sale Of Property, Plant, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.47 - 0.66 - -

Agios Pharmaceuticals Sale Of Property, Plant, Equipment Calculation

The amount earned to sell PPE.

Sale Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agios Pharmaceuticals Sale Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's Sale Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

Agios Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (MEX:AGIO) » Definitions » Sale Of Property, Plant, Equipment
Comparable Companies
RYZB ZNTL CVAC RXRX MNKD TGTX SAGE RCUS MRUS ABCL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
AGIO:USA 0HB0:UK 8AP:Germany
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Website
https://www.agios.com
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.